

ASTRAZENECA PHARMA INDIA LIMITED
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

**FINANCIAL RESULTS FOR THE
QUARTER AND HALF YEAR ENDED 30 JUNE 2006**

Rs in lakhs (except for number of shares)

Sl No.	Particulars	Quarter ended	Quarter ended	Half year ended	Half year ended	Previous Accounting year ended
		30.06.2006	30.06.2005	30.06.2006	30.06.2005	31.12.2005
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Gross sales	7,618.49	6,730.35	13,533.45	11,471.38	24,327.13
2	Excise duty on sales	623.44	593.82	1,087.21	977.93	2,085.01
3	Net sales (1-2)	6,995.05	6,136.53	12,446.24	10,493.45	22,242.12
4	Service income	130.64	71.95	262.74	118.27	293.41
5	Other income	136.16	146.55	361.69	269.31	752.28
6	Total expenditure					
	(a) Decrease in finished goods and work-in-progress	31.20	511.41	122.35	447.39	315.45
	(b) Consumption of raw materials, packing materials and traded goods	2,375.23	1,506.02	4,202.40	3,051.22	7,212.64
	(c) Personnel costs	1,113.10	925.35	2,236.87	1,849.03	3,740.38
	(d) Other expenditure	1,504.92	1,246.51	2,911.29	2,322.77	5,016.82
7	Interest	0.96	(0.33)	1.90	3.51	5.45
8	Depreciation	146.13	120.74	278.89	236.24	519.46
9	Profit before tax (3+4+5-6-7-8)	2,090.31	2,045.33	3,316.97	2,970.87	6,477.61
10	Provision for tax, net	510.24	630.29	916.95	963.51	2,145.37
11	Provision for fringe benefit tax	42.00	44.35	95.10	44.35	103.00
12	Deferred tax charge / (credit)	193.32	(8.76)	191.78	5.87	(76.57)
13	Net profit (9-10-11-12)	1,344.75	1,379.45	2,113.14	1,957.14	4,305.81
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves (as per balance sheet of previous accounting year)	-	-	-	-	12,219.54
16	Basic and diluted earnings (Rs) per share (not annualised)	5.38	5.52	8.45	7.83	17.22
17	Aggregate of non-promoter shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%

Notes :

- The above statement of financial results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at meetings held on 28 July 2006.
- The Company's sole business segment is HealthCare. The capital employed in this segment as on 30 June 2006 is Rs 14,832.67 lakhs (31 December 2005: Rs 12,719.54 lakhs).
- Status of investor complaints : a) Pending as on 1 April 2006 - 1 b) Received during the quarter - 5 c) Disposed off during the quarter - 4 d) Pending as on 30 June 2006 - 2. Out of the investor complaints pending, 1 investor complaint has been carried forward from the previous quarter which pertains to dispute on ownership of shares and 1 investor complaint pertains to non-receipt of dividend. This is in the process of being resolved.
- At the Extra-ordinary General Meeting held on 6 June 2006, the Shareholders of the Company have approved the sub-division of equity shares. A share of face value of Rs 10 each has been subdivided to 5 equity shares of face value of Rs 2 each. The effective date for the sub-division was 22 June 2006. Consequently, the number of equity shares, used for computation of earning per share has been adjusted for all the periods presented above.
- Based on the favourable order passed by the Commissioner of Income Tax - Appeals dated 15 June 2005, provision for wealth tax amounting to Rs12,164,400 created in the 2004 was reversed during the quarter ended 30 June 2005 by crediting provision for tax.
- Previous period figures have been regrouped/ reclassified, wherever necessary to conform to the current period's presentation.

**By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED**

Bangalore
Dated: 28 July 2006

BHASKER V IYER
Managing Director